Press release
Malmö, August 23, 2017
Acarix presents new frontline CAD test at European Society of Cardiology Congress, Barcelona, August 26-30.
Advanced acoustic technology detects partial obstruction of coronary arterial flow
One of the highlights of the Emerging Technology Showcase Area at the European Society of Cardiology Congress in Barcelona, will be Swedish/Danish Acarix AB`s (publ) ("Acarix") CADScor®System, an advanced, easy to use, frontline test to rule out Coronary Artery Disease (CAD) with high accuracy. Initial study results released earlier this year show that the Danish Design Award winning CADScor®System non-invasively rules out CAD with 97% negative predictive value. Following this, the CADScor®System has been commercially launched in the Nordics and Germany to both private and public cardiology centers.
In addition to seeing demonstrations of the CADScor®System on booth F140 in the Emerging Technology Showcase Area, delegates will also be able to learn about study results from Principal Investigator Morten Böttcher, MD PhD FESC and Simon Winther, MD PhD, Department of Cardiology, Herning Hospital, Denmark.
Acarix CEO Søren Rysholt Christiansen commented: "We are very pleased to be presenting CADScor®System in the Emerging Technology Showcase Area. Already CADScor®System is in clinical use and is generating interest in our initial German and Nordic target markets, and we now look forward to introducing it to a wider audience including European cardiologists and other experts attending ESC. CAD affects more than 120 million people worldwide but the current diagnostic pathway, which can rapidly escalate to imaging and coronary angiography can be significantly improved. The CADScor®System uses advanced acoustic technology to rapidly measure arterial flow in a non-invasive way and thus provide an accurate frontline assessment potentially leading to an improved triage. This will ensure patients in need of further diagnostic tests get them and that patients with symptoms unrelated to CAD do not."
About the CADScor®System
The CADScor®System uses ultra-sensitive phonocardiography combined with advanced electronics and algorithms to rule out CAD with 97% negative predictive value. CADScor®System is fast, radiation-free, non- invasive and can be performed in every standard point-of-care environment in less than 10 minutes.
In patients with suspected CAD, the current practice includes one or several examinations, i.e. stress tests, nuclear imaging, and invasive coronary angiography. In many cases, these patients are either healthy or end up not needing any treatment. The CADScor®System is designed to provide a first rapid and non-invasive, investigative step and by ruling out CAD earlier, the diagnostic pathway improves.